Research progress of CAR-T immunotherapy in solid tumors combined with new strategies

LI Mengyuan; JIANG Xiaomeng; SUN Qinyi; GUO Wei

doi:10.11665/j.issn.1000-5048.2023030101

Journal of China Pharmaceutical University > 2023 > 54(4): 443-449. > DOI: 10.11665/j.issn.1000-5048.2023030101

LI Mengyuan, JIANG Xiaomeng, SUN Qinyi, GUO Wei. Research progress of CAR-T immunotherapy in solid tumors combined with new strategies[J]. Journal of China Pharmaceutical University, 2023, 54(4): 443-449. DOI: 10.11665/j.issn.1000-5048.2023030101

Citation:

PDF (594 KB)

Research progress of CAR-T immunotherapy in solid tumors combined with new strategies

1.
School of Life Science and Technology, China Pharmaceutical University,Nanjing 211198
2.
Department of Gastroenterology, Sir Run Run Hospital,Nanjing Medical University,Nanjing 211112, China

Funds: This study was supported by the National Natural Science Foundation of China (No. 81973221) and Chinese Foundation for Hepatitis Prevention and Control — TianQing Liver Disease Research Fund Project（No. TQGB20210089）

More Information

Received Date: February 28, 2023
Revised Date: May 12, 2023

Graphical Abstract

Abstract

Abstract

In recent years, the chimeric antigen receptor T-cell (CAR-T) therapy has achieved breakthrough progress in the treatment of hematologic malignancies. However, when it comes to solid tumors, numerous challenges persist.These include limited CAR-T cell infiltration, susceptibility to T cell exhaustion, off-target effects, and more.Thus, novel therapeutic strategies are imperative to enhance the efficacy of CAR-T therapy for solid tumors. In comparison to standalone CAR-T approaches, the combination of CAR-T with other tumor treatment modalities has demonstrated remarkable effectiveness in both preclinical and clinical research.This review article summarizes the advancements in combining CAR-T with various solid tumor treatments: antibody drugs, oncolytic viruses, tumor vaccines, and nanomedicines.The objective is to furnish a theoretical foundation and novel perspectives for the development of innovative CAR-T combination strategies tailored for solid tumor therapy.
- chimeric antigen receptor T-cell (CAR-T),
- solid tumor,
- antibody drugs,
- oncolytic virus,
- cancer vaccine,
- nano-medicine

FullText(HTML)

References (50)

References

[1]	Pan K, Farrukh H, Chittepu VCSR, et al. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy[J]. J Exp Clin Cancer Res, 2022, 41(1): 119.
[2]	Zhang BL, Qin DY, Mo ZM, et al. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors[J]. Sci China Life Sci, 2016, 59(4): 340-348.
[3]	Martinez M,Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment[J]. Front Immunol, 2019, 10: 128.
[4]	Fang J, Nakamura H,Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect[J]. Adv Drug Deliv Rev, 2011, 63(3): 136-151.
[5]	Slaney CY, Kershaw MH, Darcy PK. Trafficking of T cells into tumors[J]. Cancer Res, 2014, 74(24): 7168-7174.
[6]	Kankeu Fonkoua LA, Sirpilla O, Sakemura R, et al. CAR T cell therapy and the tumor microenvironment: current challenges and opportunities[J]. Mol Ther Oncolytics, 2022, 25: 69-77.
[7]	Marofi F, Motavalli R, Safonov VA, et al. CAR T cells in solid tumors: challenges and opportunities[J]. Stem Cell Res Ther, 2021, 12(1): 81.
[8]	Goydel RS, Rader C. Antibody-based cancer therapy[J]. Oncogene, 2021, 40(21): 3655-3664.
[9]	Yu J, Song Y, Tian W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies[J]. J Hematol Oncol, 2020, 13(1): 45.
[10]	Caratelli S, Arriga R, Sconocchia T, et al. In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab[J]. Int J Cancer, 2020, 146(1): 236-247.
[11]	Marin-Acevedo JA, Kimbrough EO, Lou YY. Next generation of immune checkpoint inhibitors and beyond[J]. J Hematol Oncol, 2021, 14(1): 45.
[12]	Grosser R, Cherkassky L, Chintala N, et al. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors[J]. Cancer Cell, 2019, 36(5): 471-482.
[13]	Adusumilli PS, Zauderer MG, Rivière I, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab[J]. Cancer Discov, 2021, 11(11): 2748-2763.
[14]	Yamaguchi Y, Gibson J, Ou K, et al. PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163⁺ M2 macrophages[J]. J Immunother Cancer, 2022, 10(6): e004400.
[15]	Yang J, Yan J,Liu B. Targeting VEGF/VEGFR to modulate antitumor immunity[J]. Front Immunol, 2018, 9: 978.
[16]	Bocca P, di Carlo E, Caruana I, et al. Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model[J]. Oncoimmunology, 2017, 7(1): e1378843.
[17]	Guedan S, Alemany R. CAR-T cells and oncolytic viruses: joining forces to overcome the solid tumor challenge[J]. Front Immunol, 2018, 9: 2460.
[18]	Tang XY, Ding YS, Zhou T, et al. Tumor-tagging by oncolytic viruses: a novel strategy for CAR-T therapy against solid tumors[J]. Cancer Lett, 2021, 503: 69-74.
[19]	Ajina A, Maher J. Prospects for combined use of oncolytic viruses and CAR T-cells[J]. J Immunother Cancer, 2017, 5(1): 90.
[20]	Watanabe K, Luo YP, Da T, et al. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses[J].JCI Insight, 2018, 3(7): e99573.
[21]	Wang GQ, Zhang ZL, Zhong KH, et al. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma[J]. Mol Ther, 2023, 31(1): 134-153.
[22]	Heidbuechel JPW, Engeland CE. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies[J]. J Hematol Oncol, 2021, 14(1): 63.
[23]	Porter CE, Rosewell Shaw A, Jung Y, et al. Oncolytic adenovirus armed with BiTE, cytokine, and checkpoint inhibitor enables CAR T cells to control the growth of heterogeneous tumors[J]. Mol Ther, 2020, 28(5): 1251-1262.
[24]	Wenthe J, Naseri S, Labani-Motlagh A, et al. Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy[J]. Cancer Immunol Immunother, 2021, 70(10): 2851-2865.
[25]	Shemesh CS, Hsu JC, Hosseini I, et al. Personalized cancer vaccines: clinical landscape, challenges, and opportunities[J]. Mol Ther, 2021, 29(2): 555-570.
[26]	Liu J, Fu MY, Wang MN, et al. Cancer vaccines as promising immuno-therapeutics: platforms and current progress[J]. J Hematol Oncol, 2022, 15(1): 28.
[27]	Matsuo K, Yoshie O, Kitahata K, et al. Recent progress in dendritic cell-based cancer immunotherapy[J]. Cancers (Basel), 2021, 13(10): 2495.
[28]	Wu MR, Zhang LT, Zhang HZ, et al. CD19 chimeric antigen receptor-redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide-derived dendritic cell vaccine in leukemia[J]. Cytotherapy, 2019, 21(6): 659-670.
[29]	Reinhard K, Rengstl B, Oehm P, et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors[J]. Science, 2020, 367(6476): 446-453.
[30]	Nelde A, Rammensee HG, Walz JS. The peptide vaccine of the future[J]. Mol Cell Proteomics, 2021, 20: 100022.
[31]	Ma LY, Dichwalkar T, Chang JYH, et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor[J]. Science, 2019, 365(6449): 162-168.
[32]	Shi Y, Lammers T. Combining nanomedicine and immunotherapy[J]. Acc Chem Res, 2019, 52(6): 1543-1554.
[33]	Abdalla AME, Xiao L, Miao Y, et al. Nanotechnology promotes genetic and functional modifications of therapeutic T cells against cancer[J]. Adv Sci (Weinh), 2020, 7(10): 1903164.
[34]	Duan XP, Chan C, Lin WB. Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy[J]. Angewandte Chemie Int Ed, 2019, 58(3): 670-680.
[35]	Chen Q, Hu QY, Dukhovlinova E, et al. Photothermal therapy promotes tumor infiltration and antitumor activity of CAR T cells[J]. Adv Mater, 2019, 31(23): e1900192.
[36]	Miao L, Li JJ, Liu Q, et al. Transient and local expression of chemokine and immune checkpoint traps to treat pancreatic cancer[J]. ACS Nano, 2017, 11(9): 8690-8706.
[37]	Lian HP, Ma S, Zhao DY, et al. Cytokine therapy combined with nanomaterials participates in cancer immunotherapy[J]. Pharmaceutics, 2022, 14(12): 2606.
[38]	Jiang JY, Zhang YD, Peng K, et al. Combined delivery of a TGF-β inhibitor and an adenoviral vector expressing interleukin-12 potentiates cancer immunotherapy[J]. Acta Biomater, 2017, 61: 114-123.
[39]	Sun ZC, Li RT, Shen Y, et al. In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors[J]. J Hematol Oncol, 2022, 15(1): 29.
[40]	Zang H, Siddiqui M, Gummuluru S, et al. Ganglioside-functionalized nanoparticles for chimeric antigen receptor T-cell activation at the immunological synapse[J]. ACS Nano, 2022, 16(11): 18408-18420.
[41]	Alhallak K, Sun J, Wasden K, et al. Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy[J]. Leukemia, 2021, 35(8): 2346-2357.
[42]	Zuo YH, Zhao XP, Fan XX. Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor[J]. Pharmacol Res, 2022, 184: 106454.
[43]	Grosskopf AK, Labanieh L, Klysz DD, et al. Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors[J]. Sci Adv, 2022, 8(14): eabn8264.
[44]	Hu QY, Li HJ, Archibong E, et al. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets[J]. Nat Biomed Eng, 2021, 5(9): 1038-1047.
[45]	Cho KJ, Cho YE, Kim J. Locoregional lymphatic delivery systems using nanoparticles and hydrogels for anticancer immunotherapy[J]. Pharmaceutics, 2022, 14(12): 2752.
[46]	Wen R, Umeano AC, Kou Y, et al. Nanoparticle systems for cancer vaccine[J]. Nanomedicine (London), 2019, 14(5): 627-648.
[47]	Chen WQ, Jiang MX, Yu WJ, et al. CpG-based nanovaccines for cancer immunotherapy[J]. Int J Nanomedicine, 2021, 16: 5281-5299.
[48]	Chen H, Fan Y, Hao XX, et al. Adoptive cellular immunotherapy of tumors via effective CpG delivery to dendritic cells using dendrimer-entrapped gold nanoparticles as a gene vector[J]. J Mater Chem B, 2020, 8(23): 5052-5063.
[49]	Chen JJ, Ye ZF, Huang CF, et al. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8⁺ T cell response[J]. Proc Natl Acad Sci U S A, 2022, 119(34): e2207841119.
[50]	Ma S, Li XC, Wang XY, et al. Current progress in CAR-T cell therapy for solid tumors[J]. Int J Biol Sci, 2019, 15(12): 2548-2560.

Cited By

Cited by

Periodical cited type(0)

Other cited types(1)

Get Citation

PDF

XML

Article views (1113) PDF downloads (538) Cited by(1)

Turn off MathJax

Article Contents

Abstract

References

Research progress of CAR-T immunotherapy in solid tumors combined with new strategies

Abstract

References

Cited by

Periodical cited type(0)

Other cited types(1)

Catalog

Export File

Citation

Format

Content